» Articles » PMID: 36683048

Single-nucleus RNA Sequencing and Deep Tissue Proteomics Reveal Distinct Tumour Microenvironment in Stage-I and II Cervical Cancer

Overview
Publisher Biomed Central
Specialty Oncology
Date 2023 Jan 22
PMID 36683048
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cervical cancer (CC) is the 3 most common cancer in women and the 4 leading cause of deaths in gynaecological malignancies, yet the exact progression of CC is inconclusive, mainly due to the high complexity of the changing tumour microenvironment (TME) at different stages of tumorigenesis. Importantly, a detailed comparative single-nucleus transcriptomic analysis of tumour microenvironment (TME) of CC patients at different stages is lacking.

Methods: In this study, a total of 42,928 and 29,200 nuclei isolated from the tumour tissues of stage-I and II CC patients and subjected to single-nucleus RNA sequencing (snRNA-seq) analysis. The cell heterogeneity and functions were comparatively investigated using bioinformatic tools. In addition, label-free quantitative mass spectrometry based proteomic analysis was carried out. The proteome profiles of stage-I and II CC patients were compared, and an integrative analysis with the snRNA-seq was performed.

Results: Compared with the stage-I CC (CCI) patients, the immune response relevant signalling pathways were largely suppressed in various immune cells of the stage-II CC (CCII) patients, yet the signalling associated with cell and tissue development was enriched, as well as metabolism for energy production suggested by the upregulation of genes associated with mitochondria. This was consistent with the quantitative proteomic analysis that showed the dominance of proteins promoting cell growth and intercellular matrix development in the TME of CCII group. The interferon-α and γ responses appeared the most activated pathways in many cell populations of the CCI patients. Several collagens, such as COL12A1, COL5A1, COL4A1 and COL4A2, were found significantly upregulated in the CCII group, suggesting their roles in diagnosing CC progression. A novel transcript AC244205.1 was detected as the most upregulated gene in CCII patients, and its possible mechanistic role in CC may be investigated further.

Conclusions: Our study provides important resources for decoding the progression of CC and set the foundation for developing novel approaches for diagnosing CC and tackling the immunosuppressive TME.

Citing Articles

regulates cervical cancer by proliferative cells: mendelian randomization and single-cell transcriptomics analyses.

Wang Y, Yao J, Wei M, Jiang Q, Luo H, Lai S Transl Cancer Res. 2025; 14(1):354-370.

PMID: 39974380 PMC: 11833381. DOI: 10.21037/tcr-24-949.


Caerin 1.1/1.9-mediated antitumor immunity depends on IFNAR-Stat1 signalling of tumour infiltrating macrophage by autocrine IFNα and is enhanced by CD47 blockade.

Li J, Luo Y, Fu Q, Tang S, Zhang P, Frazer I Sci Rep. 2025; 15(1):3789.

PMID: 39885296 PMC: 11782643. DOI: 10.1038/s41598-025-87687-0.


Single-cell transcriptomics unveils multifaceted immune heterogeneity in early-onset versus late-onset cervical cancer.

Chen Q, Deng D, Zhu H, Li S World J Surg Oncol. 2025; 23(1):12.

PMID: 39810181 PMC: 11730844. DOI: 10.1186/s12957-025-03654-z.


Analysis of Lymphovascular Infiltration and Tumor-Associated Macrophages in Cervical Cancer Immunoescape.

Guan L, Xu X, Xu J, Xu G, Zhang Y, Xia H Onco Targets Ther. 2024; 17:1117-1136.

PMID: 39583248 PMC: 11585989. DOI: 10.2147/OTT.S468484.


CCL21 Induces Plasmacytoid Dendritic Cell Migration and Activation in a Mouse Model of Glioblastoma.

Zhao L, Shireman J, Probelsky S, Rigg B, Wang X, Huff W Cancers (Basel). 2024; 16(20).

PMID: 39456552 PMC: 11506458. DOI: 10.3390/cancers16203459.


References
1.
Zhang J, Rashmi R, Inkman M, Jayachandran K, Ruiz F, Waters M . Integrating imaging and RNA-seq improves outcome prediction in cervical cancer. J Clin Invest. 2021; 131(5). PMC: 7919714. DOI: 10.1172/JCI139232. View

2.
Peruzzi D, Mori F, Conforti A, Lazzaro D, de Rinaldis E, Ciliberto G . MMP11: a novel target antigen for cancer immunotherapy. Clin Cancer Res. 2009; 15(12):4104-13. DOI: 10.1158/1078-0432.CCR-08-3226. View

3.
Sun Y, Ling J, Liu L . Collagen type X alpha 1 promotes proliferation, invasion and epithelial-mesenchymal transition of cervical cancer through activation of TGF-β/Smad signaling. Physiol Int. 2022; . DOI: 10.1556/2060.2022.00006. View

4.
Xie L, Chu R, Wang K, Zhang X, Li J, Zhao Z . Prognostic Assessment of Cervical Cancer Patients by Clinical Staging and Surgical-Pathological Factor: A Support Vector Machine-Based Approach. Front Oncol. 2020; 10:1353. PMC: 7419674. DOI: 10.3389/fonc.2020.01353. View

5.
El-Gebali S, Mistry J, Bateman A, Eddy S, Luciani A, Potter S . The Pfam protein families database in 2019. Nucleic Acids Res. 2018; 47(D1):D427-D432. PMC: 6324024. DOI: 10.1093/nar/gky995. View